CME article by Motomi Toichi, MD, PhD, Director of Mental Health, Associate Professor, Health and Medical Services Center, Shiga University, Shiga, Japan; and Robert L. Findling, MD, Director, Division of Child and Adolescent Psychiatry, Associate Professor of Psychiatry, Case Western Reserve University/University Hospitals of Cleveland
Dr. Toichi has disclosed that he has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. Dr. Findling has disclosed that his research is supported in part by, he is a consultant to, and/or is on the speakers' bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, and Solvay.
The use of haloperidol, fluphenazine, risperidone, olanzapine, quetiapine, clozapine, clomipramine, fluvoxamine, fluoxetine, sertraline, paroxetine, methylphenidate, naltrexone, clonidine, and propranolol has not been approved by the U.S. Food and Drug Administration for the treatment of autism.
